Sinocelltech Group Limited Logo

Sinocelltech Group Limited

688520.SS

(2.2)
Stock Price

38,38 CNY

-4.67% ROA

26.39% ROE

-158.9x PER

Market Cap.

21.046.579.360,00 CNY

-631.98% DER

0% Yield

-5.58% NPM

Sinocelltech Group Limited Stock Analysis

Sinocelltech Group Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Sinocelltech Group Limited Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (120.97%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 PBV

The stock's low PBV ratio (-52.34x) suggests it's undervalued, making it an attractive opportunity for investors.

3 DER

The stock has a low debt to equity ratio (-627%), which means it has a small amount of debt compared to the ownership it holds

4 Revenue Growth

Over the past three years, this company's revenue has consistently grown, demonstrating a positive financial trend that makes it an appealing choice.

5 Net Profit Growth

This company's net profit has been consistently on the rise over the past three years, indicating a strong financial performance and making it an appealing investment opportunity.

6 Assets Growth

With a track record of continuous revenue growth in the last three years, this company offers a promising investment opportunity

7 ROA

The stock's ROA (-15.99%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

8 Graham Number

The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (-135), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Sinocelltech Group Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Sinocelltech Group Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Sinocelltech Group Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Sinocelltech Group Limited Revenue
Year Revenue Growth
2016 98.125.823
2017 5.992.730 -1537.41%
2018 2.945.672 -103.44%
2019 2.638.317 -11.65%
2020 328.165 -703.96%
2021 134.392.817 99.76%
2022 1.023.176.678 86.87%
2023 2.284.705.373 55.22%
2023 1.874.411.137 -21.89%
2024 2.751.252.824 31.87%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Sinocelltech Group Limited Research and Development Expenses
Year Research and Development Expenses Growth
2016 120.201.966
2017 189.173.009 36.46%
2018 434.772.521 56.49%
2019 516.175.729 15.77%
2020 610.306.752 15.42%
2021 732.662.077 16.7%
2022 886.027.093 17.31%
2023 1.236.208.726 28.33%
2023 1.065.907.301 -15.98%
2024 783.725.088 -36.01%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Sinocelltech Group Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
2016 5.534.660
2017 6.406.201 13.6%
2018 10.099.368 36.57%
2019 19.969.922 49.43%
2020 21.679.830 7.89%
2021 22.312.656 2.84%
2022 26.599.749 16.12%
2023 365.889.019 92.73%
2023 27.948.568 -1209.15%
2024 -99.393.042 128.12%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Sinocelltech Group Limited EBITDA
Year EBITDA Growth
2016 8.026.260
2017 -113.928.491 107.04%
2018 -420.180.477 72.89%
2019 -751.382.940 44.08%
2020 -656.105.690 -14.52%
2021 -782.053.384 16.1%
2022 -366.604.590 -113.32%
2023 -90.329.811 -305.85%
2023 163.632.690 155.2%
2024 1.018.778.360 83.94%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Sinocelltech Group Limited Gross Profit
Year Gross Profit Growth
2016 75.837.989
2017 3.792.770 -1899.54%
2018 2.401.520 -57.93%
2019 765.007 -213.92%
2020 268.913 -184.48%
2021 127.351.681 99.79%
2022 989.300.164 87.13%
2023 2.226.140.986 55.56%
2023 1.711.612.017 -30.06%
2024 2.506.646.140 31.72%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Sinocelltech Group Limited Net Profit
Year Net Profit Growth
2016 -12.142.949
2017 -141.279.612 91.41%
2018 -453.258.163 68.83%
2019 -805.239.487 43.71%
2020 -730.502.320 -10.23%
2021 -901.374.258 18.96%
2022 -522.016.822 -72.67%
2023 -328.427.213 -58.94%
2023 -396.018.311 17.07%
2024 206.033.428 292.21%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Sinocelltech Group Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2016 0
2017 0 0%
2018 -1 100%
2019 -2 0%
2020 -2 0%
2021 -2 50%
2022 -1 -100%
2023 0 0%
2023 -1 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Sinocelltech Group Limited Free Cashflow
Year Free Cashflow Growth
2016 -177.485.691
2017 -162.182.666 -9.44%
2018 -190.697.851 14.95%
2019 -613.483.331 68.92%
2020 -654.668.002 6.29%
2021 -1.056.680.167 38.04%
2022 -982.712.709 -7.53%
2023 -886.172.401 -10.89%
2023 -261.000.990 -239.53%
2024 -80.308.055 -225%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Sinocelltech Group Limited Operating Cashflow
Year Operating Cashflow Growth
2016 -40.279.331
2017 -93.278.608 56.82%
2018 -88.019.303 -5.98%
2019 -485.102.965 81.86%
2020 -537.405.096 9.73%
2021 -862.824.462 37.72%
2022 -427.909.674 -101.64%
2023 -380.795.433 -12.37%
2023 -198.444.852 -91.89%
2024 -42.936.420 -362.18%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Sinocelltech Group Limited Capital Expenditure
Year Capital Expenditure Growth
2016 137.206.360
2017 68.904.058 -99.13%
2018 102.678.548 32.89%
2019 128.380.366 20.02%
2020 117.262.906 -9.48%
2021 193.855.705 39.51%
2022 554.803.035 65.06%
2023 505.376.968 -9.78%
2023 62.556.138 -707.88%
2024 37.371.635 -67.39%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Sinocelltech Group Limited Equity
Year Equity Growth
2016 80.380.064
2017 167.839.027 52.11%
2018 -23.841.736 803.97%
2019 34.804.052 168.5%
2020 588.364.290 94.08%
2021 -230.990.081 354.71%
2022 -242.190.945 4.62%
2023 -439.098.665 44.84%
2023 -605.814.473 27.52%
2024 -464.735.332 -30.36%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Sinocelltech Group Limited Assets
Year Assets Growth
2016 421.676.966
2017 486.938.797 13.4%
2018 539.758.573 9.79%
2019 808.190.058 33.21%
2020 1.663.510.985 51.42%
2021 1.373.183.568 -21.14%
2022 2.735.875.608 49.81%
2023 2.847.595.363 3.92%
2023 2.718.536.171 -4.75%
2024 3.037.661.431 10.51%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Sinocelltech Group Limited Liabilities
Year Liabilities Growth
2016 341.296.902
2017 319.099.770 -6.96%
2018 563.600.309 43.38%
2019 773.386.006 27.13%
2020 1.075.146.694 28.07%
2021 1.604.173.648 32.98%
2022 2.978.066.553 46.13%
2023 3.286.694.028 9.39%
2023 3.218.995.182 -2.1%
2024 3.405.721.961 5.48%

Sinocelltech Group Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
5.33
Net Income per Share
-0.3
Price to Earning Ratio
-158.9x
Price To Sales Ratio
8.87x
POCF Ratio
-271.53
PFCF Ratio
-54.04
Price to Book Ratio
-45.88
EV to Sales
9.95
EV Over EBITDA
73.69
EV to Operating CashFlow
-304.39
EV to FreeCashFlow
-60.58
Earnings Yield
-0.01
FreeCashFlow Yield
-0.02
Market Cap
21,05 Bil.
Enterprise Value
23,59 Bil.
Graham Number
2.63
Graham NetNet
-5.41

Income Statement Metrics

Net Income per Share
-0.3
Income Quality
0.59
ROE
0.26
Return On Assets
-0.04
Return On Capital Employed
0.45
Net Income per EBT
1
EBT Per Ebit
-0.34
Ebit per Revenue
0.16
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
0.01
Research & Developement to Revenue
0.45
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.94
Operating Profit Margin
0.16
Pretax Profit Margin
-0.06
Net Profit Margin
-0.06

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
-0.93
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.17
Free CashFlow per Share
-0.87
Capex to Operating CashFlow
-4.02
Capex to Revenue
0.13
Capex to Depreciation
4.28
Return on Invested Capital
0.16
Return on Tangible Assets
-0.05
Days Sales Outstanding
95.21
Days Payables Outstanding
296.52
Days of Inventory on Hand
586.28
Receivables Turnover
3.83
Payables Turnover
1.23
Inventory Turnover
0.62
Capex per Share
0.7

Balance Sheet

Cash per Share
0,94
Book Value per Share
-0,83
Tangible Book Value per Share
-1.27
Shareholders Equity per Share
-1.03
Interest Debt per Share
6.76
Debt to Equity
-6.32
Debt to Assets
0.95
Net Debt to EBITDA
7.95
Current Ratio
0.61
Tangible Asset Value
-0,57 Bil.
Net Current Asset Value
-2,07 Bil.
Invested Capital
786823610
Working Capital
-0,85 Bil.
Intangibles to Total Assets
0.07
Average Receivables
0,55 Bil.
Average Payables
0,11 Bil.
Average Inventory
221907736.5
Debt to Market Cap
0.14

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Sinocelltech Group Limited Dividends
Year Dividends Growth

Sinocelltech Group Limited Profile

About Sinocelltech Group Limited

Sinocelltech Group Limited, a biotech company, focuses on the development of technologies for the development and manufacturing of recombinant proteins, monoclonal antibodies, and vaccines in China. The company is based in Beijing, China.

CEO
Dr. Liangzhi Xie Ph.D.
Employee
2.348
Address
No. 31 Kechuang 7th Street
Beijing, 100176

Sinocelltech Group Limited Executives & BODs

Sinocelltech Group Limited Executives & BODs
# Name Age
1 Mr. Fanbin Pan
Head of Engineering Equipment Department
70
2 Mr. Li Ming Tang
Deputy GM, Secretary of the Board & Director
70
3 Dr. Liangzhi Xie Ph.D.
Chairman of the Board & GM
70
4 Dr. Yang Wang
Deputy GM & Director
70

Sinocelltech Group Limited Competitors